Abstract 5294: Conditionally active CD28xVISTA bispecific antibodies induce myeloid-driven tumor-specific T-cell co-stimulation for improved cancer immunotherapy

癌症 免疫疗法 抗体 医学 髓系细胞 癌症研究 刺激 癌症免疫疗法 免疫学 髓样 内科学
作者
Thomas Thisted,Zhi-Gang Jiang,Zuzana Biesová,Adejumoke M. Onumajuru,Yuliya Kleschenko,Kanam Malhotra,Vikas Saxena,Arnab Mukherjee,F. Donelson Smith,Edward Htun van der Horst
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:84 (6_Supplement): 5294-5294 被引量:1
标识
DOI:10.1158/1538-7445.am2024-5294
摘要

Abstract Introduction: Tumor-specific recruitment of co-stimulatory bispecific antibodies (bsAbs) has emerged as a promising therapeutic strategy. Here, we investigated pH-selective CD28xVISTA bsAbs to act selectively within the acidic tumor microenvironment (TME). Our CD28xVISTA bsAbs are designed for tripartite “trans-activation” of CD28 in the TME, aiming for enhanced T-cell-mediated cancer cell killing while minimizing systemic T-cell activation and Cytokine Release Syndrome (CRS) risk. Experimental Procedures: We evaluated various CD28xVISTA bsAbs, focusing on a prototype 1+2 format with monovalent CD28 binding, bivalent VISTA binding and Fc receptor interaction null mutations (BS2). BS2 was tested for T-cell trans-activation using Jurkat-IL-2-luciferase reporter cells in the presence of HEK293 cells expressing membrane bound OKT3-scFv and CHO cells expressing human VISTA. BS2’s potency was further evaluated in an xCelligence-based human T-cell killing assay that dynamically monitors growth of LNCaP prostate cancer cells co-cultured with VISTA+ Kasumi-3 cells, alone or in combination with a CD3xPSMA bispecific T-cell engager. T-cell activation and proliferation were also measured using flow cytometry with CD3, CD4, CD8 and CD25 markers. Additionally, we modified BS2 to introduce pH-selective VISTA binding, limiting its activity to the TME, and tested this version in a syngeneic mouse model in combination with anti-murine PD-1 (anti-mPD-1). Finally, cytokine release from human PBMCs, co-cultured with human umbilical vein endothelial cells (HUVECs) and treated with the pH-selective BS2 (or TGN1412 as a positive control), was measured using a bead-based multiplex immune assay. Results: Our data show that the combination of anti-mPD-1 and our prototype CD28xVISTA bsAb (BS2) with pH-selective VISTA binding significantly inhibited tumor growth in vivo. In vitro, CD28xVISTA co-stimulation in trans by BS2 potentiated the activity of a CD3xPSMA bispecific T-cell engager in our human T-cell killing assay. Cytokine release assessments demonstrated negligible induction of inflammatory cytokines, indicating a favorable safety profile for this antibody. Conclusion: Our study demonstrates the feasibility of cis and trans CD28 co-stimulation using a CD28xVISTA bsAb (BS2). This approach, which bypasses the need for tumor-associated antigens (TAAs) required by other CD28xTAA bispecifics in development, suggests a potentially safer alternative for T-cell engagement and stimulation. Moreover, our novel myeloid-directed TME-selective co-stimulation strategy with a CD28xVISTA bsAb may broaden the potential for T-cell engagement approaches in solid tumors by enabling rational combinations with existing CD3xTAA T-cell engagers without competing for the same target. Citation Format: Thomas Thisted, Zhi-Gang Jiang, Zuzana Biesova, Adejumoke Onumajuru, Yuliya Kleschenko, Kanam Malhotra, Vikas Saxena, Arnab Mukherjee, F. Donelson Smith, Edward H. van der Horst. Conditionally active CD28xVISTA bispecific antibodies induce myeloid-driven tumor-specific T-cell co-stimulation for improved cancer immunotherapy [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 5294.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
不想打工完成签到,获得积分10
刚刚
刚刚
hehe完成签到,获得积分10
刚刚
Mary完成签到,获得积分10
刚刚
五月的骇客完成签到 ,获得积分10
1秒前
2秒前
彭于晏的应助被受伤白安采纳,获得10
2秒前
2秒前
qingxuan发布了新的文献求助10
3秒前
Mary发布了新的文献求助20
4秒前
遇见完成签到,获得积分10
4秒前
耶耶小豆包完成签到,获得积分10
4秒前
美母猪佩奇完成签到,获得积分10
4秒前
Always完成签到 ,获得积分10
4秒前
11完成签到,获得积分10
5秒前
侯雨润完成签到,获得积分10
6秒前
YYM完成签到 ,获得积分10
6秒前
西西完成签到,获得积分10
6秒前
秣旎完成签到,获得积分10
6秒前
喜悦的绮露完成签到 ,获得积分10
6秒前
lsm完成签到,获得积分10
7秒前
希望天下0贩的0的应助被佩琪采纳,获得10
7秒前
7秒前
丘比特的应助被粒粒采纳,获得10
8秒前
大模型的应助被虚心碧采纳,获得10
8秒前
小欣欣爱学习完成签到,获得积分10
8秒前
Yiding完成签到,获得积分10
8秒前
汤包发布了新的文献求助10
10秒前
CipherSage的应助被平常迎天采纳,获得30
11秒前
11秒前
Tuniverse_发布了新的文献求助10
11秒前
11秒前
WANG发布了新的文献求助10
12秒前
shmily完成签到 ,获得积分10
14秒前
14秒前
15秒前
15秒前
科研通AI65的应助被尘冀等待采纳,获得10
15秒前
11完成签到,获得积分10
15秒前
16秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8182014
求助须知:如何正确求助?哪些是违规求助? 9571728
关于积分的说明 21819478
捐赠科研通 7778441
什么是DOI,文献DOI怎么找? 3433580
关于科研通互助平台的介绍 2557781
邀请新用户注册赠送积分活动 2479640